| Literature DB >> 27095655 |
Jesus M Banales1, Vincenzo Cardinale2, Guido Carpino3, Marco Marzioni4, Jesper B Andersen5, Pietro Invernizzi6,7, Guro E Lind8, Trine Folseraas9, Stuart J Forbes10, Laura Fouassier11, Andreas Geier12, Diego F Calvisi13, Joachim C Mertens14, Michael Trauner15, Antonio Benedetti4, Luca Maroni4, Javier Vaquero11, Rocio I R Macias16, Chiara Raggi6, Maria J Perugorria1, Eugenio Gaudio17, Kirsten M Boberg9, Jose J G Marin16, Domenico Alvaro2.
Abstract
Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies with features of biliary tract differentiation. CCA is the second most common primary liver tumour and the incidence is increasing worldwide. CCA has high mortality owing to its aggressiveness, late diagnosis and refractory nature. In May 2015, the "European Network for the Study of Cholangiocarcinoma" (ENS-CCA: www.enscca.org or www.cholangiocarcinoma.eu) was created to promote and boost international research collaboration on the study of CCA at basic, translational and clinical level. In this Consensus Statement, we aim to provide valuable information on classifications, pathological features, risk factors, cells of origin, genetic and epigenetic modifications and current therapies available for this cancer. Moreover, future directions on basic and clinical investigations and plans for the ENS-CCA are highlighted.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27095655 DOI： 10.1038/nrgastro.2016.51
Source DB: PubMed Journal: Nat Rev Gastroenterol Hepatol ISSN： 1759-5045 Impact factor: 46.802